Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA1302 in advanced solid malignancies
NCT06596915Phase 1Recruiting
- Sponsor
- Boan Biotech
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BA1302 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) and 2 more, sponsored by Boan Biotech. Primary endpoints: Dose Limiting Toxicities at 21 days and Adverse Events at 28 days. Started Sep 2024; status: recruiting.
02
Drugs
BA1302
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)breast cancermelanoma
Beyond the preview
Go deeper on NCT06596915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596915.